- Home
- WFC vs AZN Comparison
WFC vs AZN Comparison
Compare WFC & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFC
- AZN
- Stock Information
- Founded
- WFC 1852
- AZN 1992
- Country
- WFC United States
- AZN United Kingdom
- Employees
- WFC N/A
- AZN N/A
- Industry
- WFC Major Banks
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- WFC Finance
- AZN Health Care
- Exchange
- WFC Nasdaq
- AZN Nasdaq
- Market Cap
- WFC 240.3B
- AZN 205.5B
- IPO Year
- WFC N/A
- AZN 1993
- Fundamental
- Price
- WFC $76.22
- AZN $68.81
- Analyst Decision
- WFC Buy
- AZN Strong Buy
- Analyst Count
- WFC 18
- AZN 5
- Target Price
- WFC $75.19
- AZN $92.33
- AVG Volume (30 Days)
- WFC 17.3M
- AZN 5.3M
- Earning Date
- WFC 04-11-2025
- AZN 04-29-2025
- Dividend Yield
- WFC 2.10%
- AZN 2.24%
- EPS Growth
- WFC 16.01
- AZN 22.71
- EPS
- WFC 5.57
- AZN 4.97
- Revenue
- WFC $77,254,000,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- WFC $7.98
- AZN $9.56
- Revenue Next Year
- WFC $4.76
- AZN $6.09
- P/E Ratio
- WFC $13.69
- AZN $13.84
- Revenue Growth
- WFC N/A
- AZN 15.48
- 52 Week Low
- WFC $50.15
- AZN $61.24
- 52 Week High
- WFC $81.50
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- WFC 66.40
- AZN 48.21
- Support Level
- WFC $75.32
- AZN $66.16
- Resistance Level
- WFC $76.52
- AZN $68.95
- Average True Range (ATR)
- WFC 1.49
- AZN 1.40
- MACD
- WFC 0.52
- AZN -0.11
- Stochastic Oscillator
- WFC 95.28
- AZN 40.58
About WFC Wells Fargo & Company
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.